Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04164901 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 15, 2019
Last Update Posted : May 17, 2022
|
Sponsor:
Institut de Recherches Internationales Servier
Information provided by (Responsible Party):
Servier ( Institut de Recherches Internationales Servier )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | October 2024 |
| Estimated Study Completion Date : | August 2027 |